In a week marked by volatility and geopolitical tensions, global markets have faced renewed challenges, with major U.S. stock indexes experiencing declines amid trade concerns. Despite these fluctuations, the upward revision of U.S. GDP growth offers a silver lining, underscoring potential opportunities for investors seeking growth companies with strong fundamentals. In this environment, stocks with high insider ownership can be particularly appealing as they often indicate confidence from those closest to the company’s operations and strategic vision.

Top 10 Growth Companies With High Insider Ownership Globally

Name	Insider Ownership	Earnings Growth
UTI (KOSDAQ:A179900)	24.7%	120.7%
Seers Technology (KOSDAQ:A458870)	32%	78.8%
Modetour Network (KOSDAQ:A080160)	12.7%	41.8%
Loadstar Capital K.K (TSE:3482)	31%	23.6%
Laopu Gold (SEHK:6181)	34.8%	34.4%
KebNi (OM:KEBNI B)	35%	73%
J&V Energy Technology (TWSE:6869)	17.9%	27.1%
FUNDINNOInc (TSE:462A)	33.4%	41.5%
Fulin Precision (SZSE:300432)	10.6%	63.7%
CD Projekt (WSE:CDR)	29.7%	48.7%

Click here to see the full list of 829 stocks from our Fast Growing Global Companies With High Insider Ownership screener.

Let's dive into some prime choices out of the screener.

Aimed Bio (KOSDAQ:A0009K0)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Aimed Bio Inc. focuses on developing therapeutic solutions for brain diseases, including neuro-oncological and degenerative conditions, with a market cap of approximately ₩3.70 trillion.

Operations: The company generates revenue of ₩20.71 billion by researching, developing, producing, and selling antibody-based therapeutics for brain diseases.

Insider Ownership: 34.4%

Earnings Growth Forecast: 87.4% p.a.

Aimed Bio recently completed a KRW 70.73 billion IPO, signaling strong market interest. The company is poised for significant growth, with revenue expected to increase by 31.9% annually, outpacing the Korean market's average. Earnings are forecasted to grow at an impressive 87.42% per year, with profitability anticipated in three years. Despite high share price volatility and trading below estimated fair value by 20.9%, insider transactions remain stable without substantial buying or selling activity recently.

• Click here to discover the nuances of Aimed Bio with our detailed analytical future growth report.
• Insights from our recent valuation report point to the potential overvaluation of Aimed Bio shares in the market.

Oscotec (KOSDAQ:A039200)

Simply Wall St Growth Rating: ★★★★★★

Overview: Oscotec Inc. is a biotechnology company involved in drug development, functional materials, and dental bone graft material businesses, with a market cap of ₩2 trillion.

Operations: The company's revenue segments are comprised of the New Drug Business Division at ₩19.91 billion, the Medical Business Sector at ₩1.84 billion, Functional Materials at ₩407.81 million, and the Food Business at ₩1.08 billion.

Insider Ownership: 12.7%

Earnings Growth Forecast: 116.4% p.a.

Oscotec's growth potential is underscored by its forecasted revenue increase of 78.2% annually, outpacing the Korean market average. The company is expected to become profitable in three years, with earnings projected to grow significantly at 116.36% per year. Despite recent financial losses and high share price volatility, Oscotec trades well below its estimated fair value and maintains stable insider ownership without significant recent buying or selling activity.

• Dive into the specifics of Oscotec here with our thorough growth forecast report.
• Upon reviewing our latest valuation report, Oscotec's share price might be too optimistic.

BHI (KOSDAQ:A083650)

Simply Wall St Growth Rating: ★★★★★☆

Overview: BHI Co., Ltd. develops, manufactures, and supplies power plant equipment globally, with a market cap of ₩2.25 billion.

Operations: The company's revenue primarily comes from its Machinery & Industrial Equipment segment, generating ₩656.37 million.

Insider Ownership: 34.4%

Earnings Growth Forecast: 27.2% p.a.

BHI's strategic alliance with Red Post Energy and BASIC Equipment aims to accelerate U.S. power generation projects, leveraging BHI’s manufacturing and financing capabilities. This positions BHI for growth amid rising energy demand driven by data centers and AI infrastructure. Despite a volatile share price, earnings grew significantly over the past year, with forecasts indicating continued revenue growth of 28.6% annually, surpassing market averages. Recent earnings reports show substantial profit increases, reflecting strong operational performance.

• Unlock comprehensive insights into our analysis of BHI stock in this growth report.
• In light of our recent valuation report, it seems possible that BHI is trading beyond its estimated value.

Summing It All Up

• Gain an insight into the universe of 829 Fast Growing Global Companies With High Insider Ownership by clicking here.
• Seeking Other Investments? Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.